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Abstract
Background:  The major psychoactive cannabinoid compound of marijuana, delta-9
tetrahydrocannabinol (THC), has been shown to modulate immune responses and lymphocyte
function. After primary infection the viral DNA genome of gamma herpesviruses persists in
lymphoid cell nuclei in a latent episomal circular form. In response to extracellular signals, the latent
virus can be activated, which leads to production of infectious virus progeny. Therefore, we
evaluated the potential effects of THC on gamma herpesvirus replication.
Methods:  Tissue cultures infected with various gamma herpesviruses were cultured in the
presence of increasing concentrations of THC and the amount of viral DNA or infectious virus
yield was compared to those of control cultures. The effect of THC on Kaposi's Sarcoma
Associated Herpesvirus (KSHV) and Epstein-Barr virus (EBV) replication was measured by the
Gardella method and replication of herpesvirus saimiri (HVS) of monkeys, murine gamma
herpesvirus 68 (MHV 68), and herpes simplex type 1 (HSV-1) was measured by yield reduction
assays. Inhibition of the immediate early ORF 50 gene promoter activity was measured by the dual
luciferase method.
Results: Micromolar concentrations of THC inhibit KSHV and EBV reactivation in virus infected/
immortalized B cells. THC also strongly inhibits lytic replication of MHV 68 and HVS in vitro.
Importantly, concentrations of THC that inhibit virus replication of gamma herpesviruses have no
effect on cell growth or HSV-1 replication, indicating selectivity. THC was shown to selectively
inhibit the immediate early ORF 50 gene promoter of KSHV and MHV 68.
Conclusions: THC specifically targets viral and/or cellular mechanisms required for replication
and possibly shared by these gamma herpesviruses, and the endocannabinoid system is possibly
involved in regulating gamma herpesvirus latency and lytic replication. The immediate early gene
ORF 50 promoter activity was specifically inhibited by THC. These studies may also provide the
foundation for the development of antiviral strategies utilizing non-psychoactive derivatives of
THC.
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Background
The Kaposi's Sarcoma-Associated Herpesvirus (KSHV/
HHV-8) is the likely cause of Kaposi's sarcoma in AIDS
patients, aging individuals and organ transplant patients
[for review, see [1]]. KSHV is also implicated in AIDS-asso-
ciated primary effusion lymphoma (PEL) and a subset of
cases of the lymphoproliferative disorder multicentric
Castleman's disease. Epstein-Barr virus (EBV) belongs to
the same group of herpesviruses and is also involved in
human malignancies such as Burkitt's lymphoma, Hodg-
kin's disease, nasopharingeal carcinoma, and AIDS-asso-
ciated lymphoma [for review, see [2]]. Related viruses
such as herpesvirus saimiri (HVS) of monkeys and the
murine gamma herpesvirus 68 (MHV-68) have been
developed as animal models [3-7]. The DNA genomes of
these oncogenic viruses persist in nuclei of lymphoid cells
in a latent episomal circular form and a few of these cells
can produce small amounts of infectious virus. In
response to extracellular signals, the latent virus can be
reactivated leading to production of more infectious virus
progeny. This switch from latent to lytic infection is
thought to be important in the pathogenesis of herpesvi-
ruses and the spread of infection within the organism and
among individuals.
Reactivation of latent virus is often initiated by extracellu-
lar signals activating through receptors and various tran-
scription factors. Transcription factors activate the
promoter of the critical viral gene open reading frame 50
(ORF 50) of KSHV, HVS, MHV 68 or its homologue Rta of
EBV [8-16]. The ORF 50 protein is also a transcription fac-
tor and further boosts production of its own mRNA
[10,13,16]. An important function of ORF50/Rta is to
activate early lytic genes [1,2] involved in DNA synthesis.
After synthesis of early proteins, the process culminates
with expression of late genes leading to production of vir-
ion components, virus assembly, release of progeny virus
and cell death.
The major psychoactive cannabinoid compound of mari-
juana, ∆9 tetrahydrocannabinol (THC), has been shown
to modulate and primarily suppress immune responses
against various pathogens [for review see [17,18]]. THC
binds to and activates either one of the two cannabinoid
receptors (CB1 and CB2) located on the surface of both
brain and lymphoid cells [17-26]. CB1 and CB2 belong to
the family of G protein-coupled receptors characterized by
seven transmembrane loops interacting with the ligand
on the outer surface of the cell. The receptors also contain
an intracellular signaling domain. Several endogenous
natural ligands of the CB receptor family termed endocan-
nabinoids have been described. One example is ananda-
mide, a lipid eicosanoid compound generated by the
arachidonic acid pathway. The CB receptors are conserved
through various vertebrate species including mammals
and even fish. They have been shown in various tissues to
modulate signaling and gene activation in response to
short-lived endocannabinoid ligands or THC. However,
THC has been also proposed to influence cellular function
by other mechanisms due to its hydrophobic nature and
likely association with lipid structures such as cell mem-
branes [for review, see [17,18]]. This membrane-mediated
effect is clearly less specific as all types of cells may be sub-
ject to it.
Since THC is an immune modulator we hypothesized that
it may have an effect on gamma herpesvirus replication
and/or latency. The data presented show that THC inhib-
its reactivation and lytic replication of these herpesviruses,
possibly through inhibition of the ORF 50 promoter.
Methods
Tissue culture cell lines, virus, and THC
The KSHV positive primary effusion lymphoma cell line
BCBL-1 isolated by Don Ganem and co-workers [27], and
BC-3 isolated by Ethel Cesarman and co-workers [28],
were obtained through the US National Institutes of
Health AIDS Research and Reference Reagent Program
(Rockville, MD, USA) and from the American Type Cul-
ture Collection (Manassas, VA, USA). The EBV positive
P3HR1 cell line was from George Miller [29]. MHV 68 was
obtained from Jeffrey Sample (St. Jude Children's
Research Hospital, Memphis TN USA). NIH3T12 cells
were from Samuel Speck (Yerkes Primate Research Center,
Emory University, Atlanta, GA, USA). HVS strain 484 was
isolated as described [30]. Owl monkey kidney (OMK)
cells were from Danny Daniel (New England Research Pri-
mate Center, Southborough, MA, USA). THC was
obtained from the National Institute on Drug Abuse, NIH
(Bethesda, MD, USA). Three independent batches of syn-
thetic THC were tested that gave very similar results. The
purity of these THC preparations exceeded 99%.
Antiviral assay based on the Gardella gel method
Cell suspensions were loaded in wells of a vertical agarose
gel as described [31,32]. The cell layer was then overlaid
with a lysis solution containing SDS and pronase resulting
in gentle cell lysis and liberation of cellular and viral DNA.
The gel was subjected to electrophoresis. Latent episomal
DNA migrates much more slowly in these gels than linear
replicating DNA [31,32]. After electrophoresis, Southern
blotting was performed; DNA was transferred to nitrocel-
lulose followed by hybridization with radiolabeled
cloned viral DNA as described [32]. Radioactive images
were analyzed and quantitated by a phosphoimager. The
antiviral effect (IC50) was quantitated by comparing the
values obtained from the episomal bands with those from
linear bands as described [32].BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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Virus yield reduction and cytotoxicity assays
NIH3T12 cells were infected with MHV 68, OMK cells
with HVS, and both cell types with HSV-1 at a multiplicity
of infection of 2 in the presence or absence of various con-
centrations of THC dissolved in DMSO. Control cultures
were treated with DMSO. IC50 was determined by meas-
uring virus titers in THC treated and control samples after
one cycle of freeze-thawing of the cultures. Additional
controls were uninfected cells grown in the presence of
THC or DMSO. THC or DMSO was present throughout
the experiment.
Dual luciferase promoter assays
To evaluate the effect of THC on the KSHV ORF 50 pro-
moter, a DNA fragment corresponding to the promoter
region upstream of the mapped mRNAs [reference [9],
nucleotides 70513–71513] was cloned into the basic fire-
fly luciferase vector (Promega, Inc., Madison Wisconsin).
To assay the effect of THC on the MHV 68 ORF 50 gene, a
DNA fragment containing the 0.4 kb full length ORF 50
promoter (nucleotides 66242–66652) cloned upstream
of the firefly luciferase was provided by Dr. Samuel Speck
[46,47]. About 5 µg KSHV ORF 50 firefly plasmid DNA
was transfected into BCBL-1 cells. About 5 µg MHV 68
ORF 50 firefly plasmid DNA was transfected into NIH312
cells. Control renilla luciferase expression vector (under
the control of the CMV immediate early promoter) was
included and co-transfected along with the ORF 50
reporter constructs. Cells were incubated for 48 h with
either 5 µg/ml THC solution or an equal amount of
DMSO. Luciferase activities were determined using a dual
luminometer.
Results
THC inhibits KSHV and EBV DNA replication
To evaluate the effect of THC on KSHV replication, we
selected BCBL-1 and BC-3 lymphoblastoid cells because
these cultures spontaneously produce small amounts of
virus, and we used a previously published antiviral drug
testing protocol [32] to determine whether THC induces
or inhibits virus replication. Dead cells from BCBL-1 or
BC-3 lymphoblastoid cell cultures were removed by Ficoll
gradients. Cells were cultured in RPMI 1640 growth
medium containing 10% serum for 3 days in the presence
or absence of various concentrations of THC (dissolved in
DMSO). Control cells were cultured in the presence of
0.1% DMSO (this concentration of DMSO was also used
in THC treated cultures). Cells were suspended and
loaded in wells of a vertical agarose gel, then overlaid with
a lysis buffer to remove proteins from DNA. After lysis,
slowly migrating episomal DNA representing the resident
latent viral genome, and fast migrating linear DNA repre-
senting lytic virus replication, were separated by electro-
phoresis. After electrophoresis, viral DNA was visualized
by Southern blotting. Figure 1, left panel shows that con-
trol DMSO-treated BCBL-1 cells spontaneously produce a
small amount of linear DNA, indicating lytic replication/
reactivation in a subpopulation of the cells. Various con-
centrations of THC showed concentration-dependent
inhibition of linear but not episomal KSHV DNA. These
data were reproducible and similar observations were
made in five independent experiments. Based on these
experiments we calculated the 50% inhibitory concentra-
tion (IC50) of THC at 1 µg/ml or about 3.3 µM.
To evaluate whether another KSHV strain is also suscepti-
ble to THC, the BC-3 cell line was also tested. In these
THC Inhibits of KSHV and EBV linear DNA replication Figure 1
THC Inhibits of KSHV and EBV linear DNA replica-
tion. BCBL-1 or P3HR1 cell cultures were grown in stand-
ard RPMI/fetal calf serum medium. Cultures were 
supplemented with either various concentrations of THC 
dissolved in DMSO (as indicated) or with equivalent volumes 
of DMSO. After three days, cells were analyzed for latent 
episomal and lytic linear viral genomes as described [31,32]. 
Briefly, 106 cells were loaded in wells of a vertical agarose gel 
then overlaid with a lysis solution containing SDS and pro-
nase, resulting in gentle cell lysis and liberation of cellular and 
viral DNA. The gel was subjected to electrophoresis. After 
electrophoresis, Southern blotting was performed and DNA 
was transferred to nitrocellulose followed by hybridization 
with radiolabeled overlapping cosmid clone probes of KSHV, 
representing the entire genome, as described [32] (left 
panel) or with radiolabeled cloned Bam W fragment of EBV 
(right panel). Latent episomal DNA migrates much more 
slowly in these gels than linear replicating DNA [31,32]. 
Arrows on the autoradiograms indicate the position of both 
species of DNA.BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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cells, THC had a similar inhibitory effect on KSHV reacti-
vation as observed with BCBL-1 cells (not shown).
Two experiments analogous to the one described for
KSHV were performed with the EBV transformed B cell
line P3HR1. P3HR1 cell cultures were grown in the pres-
ence of the phorbol ester TPA, because EBV did not reacti-
vate spontaneously and TPA was essential to induce lytic
EBV replication. The cultures were also supplemented
with either various concentrations of THC dissolved in
DMSO or with equivalent volumes of DMSO. Fig. 1, right
panel, shows a representative experiment. The autoradio-
gram indicates that THC inhibited EBV linear DNA syn-
thesis. Based on quantitative analysis of the radioactive
bands and extrapolation of data, the 50% inhibitory con-
centration (IC50) for THC was estimated at around 0.9 µg/
ml or about 3 µM.
THC inhibits MHV 68 and HVS lytic replication in 
monolayer cells
We examined the effects of THC on the replication of
MHV68 and HVS, two rhadinoviruses related to KSHV
and to lesser extent to EBV. These viruses can infect mon-
olayer cells and are suitable for testing the effects of com-
pounds on lytic virus replication by virus yield reduction
assays, a more widely used test for evaluating antiviral
drugs. NIH3T12 cells were infected with MHV68 at a mul-
tiplicity of infection of 2 in the presence or absence of var-
ious concentrations of THC dissolved in DMSO. Control
cultures were treated with DMSO. THC or DMSO was
present throughout the experiment. Cell cultures were
incubated for 48 h. As shown in Figure 2, a typical full
cytopathic effect of MHV 68 was observed in the control
infected cell culture treated with DMSO; most adherent
cells become detached from the plate, and remaining
loosely adhered cells were round and denser than unin-
fected controls. However, when infected cells were cul-
tured in the presence of 1.25 µg/ml or higher
concentrations of THC, they remained indistinguishable
from uninfected control cells and remained adhered to
the plate. The effect of 0.6 µg/ml of THC was intermediate
between uninfected cells and the full cytopathic effect.
These results indicated a protective effect of THC against
destruction of host cells by the virus and suggested that
THC may inhibit MHV 68 replication. Similar results were
obtained with HVS in owl monkey kidney cells (not
shown).
To quantitatively determine antiviral effects of THC, yield
reduction assays were performed. NIH3T12 cell cultures
were infected with MHV 68 and incubated with THC or
DMSO dilutions for 48 h. Cell-associated virus was
liberated by freeze-thawing. After low speed centrifuga-
tion, virus titer was determined in the culture superna-
tants. Figure 3 shows that virus yield (expressed as
infectious units of virus per ml) was highly significantly
inhibited by THC. Inhibition of virus yield was over 300-
fold at 10 µg/ml THC. The 50% inhibitory concentration
(IC50) was estimated at around 0.6 µg/ml, equivalent to
about 1.9 µM. Similar results were obtained from two
independent experiments. Similar and reproducible
results were obtained with HVS in monkey kidney cells
(not shown).
THC inhibits MHV 68 cytopathic effect in NIH3T12 cells Figure 2
THC inhibits MHV 68 cytopathic effect in NIH3T12 
cells. Photograph of NIH3T12 infected with MHV 68 at a 
multiplicity of 2. Plates were cultured for 48 h in the pres-
ence or absence of various concentrations of THC (0.625–10 
µg/ml) or equivalent volumes of DMSO.
THC inhibits MHV 68 virus yield in NIH3T12 cells Figure 3
THC inhibits MHV 68 virus yield in NIH3T12 cells. 
NIH3T12 monolayer cultures propagated in 24-well plates 
were infected and cultured in the presence of various con-
centrations of THC or equivalent DMSO. Forty-eight hours 
after infection, control cultures showed complete cytopathic 
effect and destruction of cells. To liberate cell-associated 
virus, cultures were subjected to a cycle of freeze-thawing; 
cells were homogenized and virus was titrated by end point 
dilution in 96-well plates.BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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THC is not cytotoxic to murine NIH3T12 or owl monkey 
kidney (OMK) cells
Because the observed effects might be due to a non-spe-
cific toxic effect of THC, we tested whether THC alters cell
division or morphology in NIH3T12 and owl monkey
kidney (OMK) cells. Monolayers of these cells were pre-
pared at about 25% confluency and cultured for 2 days in
the presence of THC concentrations ranging 0.6–10 µg/
ml. A series of photographs (Figure 4) show that THC
treated cultures were indistinguishable from control cul-
tures, formed confluent monolayers, and showed no
altered morphology. Owl monkey kidney (OMK) cells
also showed no toxicity in an analogous experiment (not
shown).
The effect of higher THC concentrations on cell division
was also determined. Exponentially growing BCBL-1 or
NIH12 cells were cultured for two days in the presence of
various concentrations of THC or DMSO and cell counts
were determined. The 50% cell division inhibitory
concentration of THC for BCBL-1 cells was around 33 µM.
NIH3T12 cells were less sensitive and the 50% inhibitory
concentration was around 99 µM (not shown).
THC has no comparable effect on HSV-1 lytic replication
We next examined whether or not the THC inhibitory
effect can be observed against other herpesviruses and
tested whether drug treatment suppresses the replication
of the alpha herpesvirus, HSV-1. Monolayers of NIH3T12
were prepared, infected with about 100 infectious units of
HSV-1, and cultured for 3 days in the presence of THC
concentrations ranging 0.6–10 µg/ml. A series of photo-
graphs shows (Figure 5) that typical plaques developed in
THC treated cultures, indistinguishable from those in con-
trol cultures. HSV-1 replication in OMK was also unaf-
fected by THC in an analogous experiment (not shown).
We also examined the effects of THC on production of
HSV-1 virus yield in NIH3T12 cells. Cells were infected
with HSV-1 at a multiplicity of infection of 2 in the pres-
ence or absence of various concentrations of THC dis-
solved in DMSO. Control cultures were treated with
DMSO. THC or DMSO was present throughout the exper-
iment. Cell cultures were incubated for 24 h and cell-asso-
ciated virus was liberated by freeze-thawing. After low
speed centrifugation the HSV-1 titer was determined in
the culture supernatants. Figure 6 shows that THC had no
significant inhibitory effect on replication of HSV-1 in
NIH3T12 cells.
THC inhibits the ORF 50 promoter
To evaluate the effect of THC on the MHV 68 and KSHV
ORF 50 promoters, luciferase reporter assays were per-
formed. To assay the effect of THC on the MHV 68 gene,
a DNA construct published by the Speck laboratory
[46,47] containing the 0.5 kb full length ORF 50 pro-
moter cloned upstream of the firefly luciferase was trans-
fected into NIH312 cells. Control renilla luciferase
expression vector (under the control of the CMV immedi-
ate early promoter) was included and co-transfected with
the ORF 50 reporter. Cells were incubated for 48 h with
either 5 µg/ml THC or equal amount of DMSO. Luciferase
THC is not toxic to NIH3T12 cells Figure 4
THC is not toxic to NIH3T12 cells. NIH3T12 cells 
seeded at about 1/4th of confluency were cultured for 48 h 
in the presence of various concentrations of THC (0.625–10 
µg/ml) and photographed.
THC has no significant effect on plaque formation of HSV-1  in NIH3T12 cells Figure 5
THC has no significant effect on plaque formation of 
HSV-1 in NIH3T12 cells. NIH3T12 monolayer cultures 
propagated in 6-well plates were infected with about 100 
infectious units of HSV-1 per plate and cultured in the pres-
ence of various concentrations of THC or equivalent DMSO 
solvent. Photographs were taken four days after infection.BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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activities were determined using a dual luminometer. The
results show (Table 1) that 5 µg/ml THC suppressed the
ORF 50 promoter about 7.4 fold. In contrast, the control
CMV promoter activity was only reduced by 35%. Similar
results were obtained with the KSHV ORF 50 promoter
construct containing 1 kb of the promoter sequence. In
the transfected BCBL-1 cells, 5 µg/ml THC inhibited the
ORF 50-driven luciferase activity almost 4-fold. Interest-
ingly, the co-transfected CMV promoter was slightly stim-
ulated by THC in these cells. These results were obtained
from three independent transfection experiments for both
the MHV 68 and KSHV promoter assays.
Cannabinoid receptor antagonists can reverse the 
inhibitory effect of THC on KSHV replication
To investigate whether the observed antiviral effects of
THC are mediated through the cannabinoid receptors,
two antagonists of THC, SR141716A (which acts on CB1)
and SR144528 (which inhibits CB2; a gift from Dr. Pierre
Casallas, Sanofi Recherche), were tested in the standard
BCBL-1 KSHV reactivation assay (Figure 7). BCBL-1 cells
were incubated with or without THC and in the presence
of these compounds. The THC inhibition of KSHV DNA
synthesis was not reversed by treatment with a single
receptor antagonist (not shown). The antagonists had no
effect on spontaneous KSHV reactivation. However, Fig-
ure 7 shows that they reversed the inhibition of linear
DNA synthesis by 1.25 µg/ml THC.
Discussion
To summarize the antiviral effects of THC and to compare
THC with well-characterized antiviral drugs, we compiled
data from the literature as well as from our own experi-
mental results. Table 2 shows the 50% inhibitory concen-
trations (IC50) of four known antiviral drugs and of THC.
Data on the antiviral effects of acyclovir, PFA and ganci-
clovir on KSHV were obtained from our Gardella gel
assays [32]. Usherwood et al. [33] also used a Gardella gel-
based assay to determine the effect of acyclovir against
MHV 68 in transformed B cell line S11. The data regarding
the effects of four antiviral drugs against MHV 68 and on
cell division are from the work of Neyts and De Clercq
[34] using standard lytic virus replication inhibition
assays on monolayers. The THC antiviral results are from
the data described in this paper (Gardella gels for KSHV
using BCBL-1 cells and NIH12 antiviral assays for MHV
68). These data suggest that THC is a potent and selective
antiviral agent against KSHV comparable with some well-
characterized anti-herpesvirus compounds. THC is even
more potent and selective against MHV 68 than acyclovir,
ganciclovir and foscarnet. Cidofovir appears to be most
potent in these in vitro experiments; however, this drug is
Table 1: Relative luciferase activity of extracts from control and THC treated cells. NIH 3T3 cells co-transfected with MHV 68 ORF 50 
plus CMV control (top rows of the table). BCBL-1 cells were co-transfected with the KSHV ORF 50 plus CMV control (bottom rows of 
the table). Data represent averages from three independent co-transfection experiments.
Treatment of NIH 3T3 cells MHV 68 ORF 50 promoter (firefly 
luciferase)
CMV renilla luciferase
DMSO 100% +/- 14% 100% +/- 11%
5 µg/ml THC 13.5% +/- 1.5% 65.8% +/- 9%
Treatment of BCBL-1 cells KSHV ORF 50 (firefly luciferase) CMV renilla luciferase
DMSO 100% +/- 14% 100% +/- 3%
5 µg/ml THC 28% +/- 13% 128% +/- 3%
THC has no significant effect on virus yield of HSV-1 in  NIH3T12 cells Figure 6
THC has no significant effect on virus yield of HSV-1 
in NIH3T12 cells. NIH3T12 monolayer cultures propa-
gated in 24-well plates were infected with HSV-1 at a multi-
plicity of 2 and cultured in the presence of various 
concentrations of THC or equivalent DMSO. Twenty-four 
hours after infection, all cultures showed complete cyto-
pathic effect and destruction of cells. To liberate cell-associ-
ated virus, cultures were subjected to a cycle of freeze-
thawing; cells were homogenized and virus was titrated.BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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known to cause serious side effects and is toxic to the kid-
ney in humans.
As outlined earlier, THC can modulate and inhibit the
activation of immune cells, so it is not entirely surprising
that it can down-regulate the reactivation of viruses resid-
ing in lymphocytes, as shown by the data. However, the
antiviral effect of THC is not cell specific, since MHV 68
and HVS replication was also strongly inhibited by THC
in NIH3T12 or owl monkey kidney monolayer cell
cultures. This observation suggests that THC either
directly or indirectly targets a viral gene shared by these
herpesviruses.
The data presented in Figure 7 suggest that THC may
inhibit KSHV replication through the cannabinoid recep-
tors. When BCBL-1 cells were treated with THC the recep-
tor antagonists partially reversed this effect, suggesting a
role for the CB receptors expressed by BCBL-1 cells. How-
ever, more studies are required to evaluate whether CB1,
CB2 or both receptors are involved. As discussed in the
Introduction, ORF 50/Rta is a critical gene for both
reactivation of latent virus and lytic replication in monol-
ayers. Interestingly, ORF 50/Rta activation involves cAMP
signaling [12,35]. In contrast, cannabinoid receptor bind-
ing has been shown to down-regulate the level of
activated CREB through a decrease in cyclic AMP synthesis
[17,18,26,36]. Therefore, one possible explanation is that
THC inhibits cAMP signaling, leading to decrease of ORF
50/Rta-mediated transcription and block of virus
replication. This antiviral mechanism of THC is supported
by our data. Luciferase reporter assays showed that in the
presence of THC, initiation of transcription of ORF 50
mRNA in both KSHV and MHV 68 is markedly reduced
(4-fold and 7.4-fold, respectively) as compared with the
CMV immediate early promoter. These data suggest
selective inhibition of the ORF 50 promoter of MHV 68
and KSHV by THC. However, it is also anticipated that
THC may also block other cellular and viral genes,, as this
drug has been shown to cause a wide range of changes in
lymphocyte gene expression [17,18].
Conclusions
Early studies have attempted to evaluate whether THC has
effects on HSV-1 and HSV-2 replication [37-44]. Most of
these studies concluded that THC directly or indirectly
enhances replication/reactivation of these viruses,
although Lancz et al. [42] showed that a very high concen-
tration (330 µM) decreases the infectivity of virions. Our
data presented in this paper show no effect of THC on
HSV replication at lower concentrations. To resolve these
conflicting observations, investigation of this issue should
continue in the light of new advances in herpesvirus
molecular biology and cannabinoid research.
Interestingly, statistical analysis indicates a lower inci-
dence of Kaposi's sarcoma in HIV positive women using
non-intravenous drugs [45]. About 5.4% of HIV positive
women with no drug use developed KS, whereas none of
the 47 women in this study who only used marijuana suf-
fered from KS [ref. [45], and James Goedert, personal
communication]. This report, however, involved
relatively few individuals so further analysis of a larger
cohort is warranted.
We believe that studies on cannabinoids and herpesvi-
ruses are important to continue because there are obvious
potential benefits. Better understanding may lead to the
development of specific non-psychoactive drugs that may
inhibit reactivation of oncogenic herpesviruses.
Table 2: Comparison of 50% antiviral and cell division inhibitory concentrations (IC50) and selectivity (viral versus cellular IC50) of 
selected antiviral drugs and THC
Inhibitor compound KSHV IC50 (µM) Cellular IC50 (µM) Selectivity index (viral versus 
cellular IC50)
Acyclovir 75 [ref. 32] Not done
Ganciclovir 5.1 [ref. 32] Not done
Foscarnet 97 [ref. 32] Not done
Cidofovir 0.05 [ref. 32] Not done
THC 3.3 (this work) 33 (this work) 10 (this work)
MHV 68 IC50 (µM)
Acyclovir 6 [ref. 34]
100 [ref. 33]
182 [ref. 34] 30 [ref. 34]
Ganciclovir 28 [ref. 34] 108 [ref. 34] 3.7 [ref. 34]
Foscarnet 120 [ref. 34] 1413 [ref. 34] 11 [ref. 34]
Cidofovir 0.08 [ref. 34] 78 [ref. 34] 10,000 [ref. 34]
THC 1.9 (this work) 99 (this work) 52 (this work)BMC Medicine 2004, 2:34 http://www.biomedcentral.com/1741-7015/2/34
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